Zacks Research Has Negative Estimate for Perrigo Q1 Earnings

Key Points

• Zacks Research cut Perrigo’s Q1 2028 EPS estimate to $0.49 from $0.70, while also reducing several 2026–2028 forecasts, signaling weaker expected earnings momentum.
• Perrigo’s analyst consensus remains “Hold,” with one Buy, four Hold and one Sell rating and an average price target of $19.33.
• The company recently reported quarterly EPS of $0.50, beating expectations of $0.39, and declared a $0.29 quarterly dividend, equal to an annualized yield of about 8.1%.

Perrigo Company plc (NYSE:PRGO - Free Report) - Stock analysts at Zacks Research lowered their Q1 2028 EPS estimates for shares of Perrigo in a report issued on Wednesday, August 26th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $0.49 for the quarter, down from their previous estimate of $0.70. The consensus estimate for Perrigo's current full-year earnings is $2.18 per share.

Other research analysts have also issued reports about the stock. Wall Street Zen upgraded shares of Perrigo from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. Weiss Ratings raised shares of Perrigo from a "sell (d-)" rating to a "sell (d)" rating in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Perrigo presently has an average rating of "Hold" and a consensus price target of $19.33.

Perrigo Stock Down 2.8%

Shares of NYSE:PRGO opened at $14.35 on Friday. The company has a quick ratio of 1.32, a current ratio of 2.32 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $1.99 billion, a P/E ratio of -1.15, a P/E/G ratio of 1.69 and a beta of 0.51. Perrigo has a 52-week low of $9.23 and a 52-week high of $23.98. The stock's fifty day simple moving average is $11.40 and its 200-day simple moving average is $11.42.

Perrigo (NYSE:PRGO - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.11. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. Perrigo had a positive return on equity of 11.25% and a negative net margin of 41.85%.The company's quarterly revenue was down 3.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.06) EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS.

Perrigo Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 28th will be given a dividend of $0.29 per share. The ex-dividend date of this dividend is Friday, August 28th. This represents a $1.16 annualized dividend and a yield of 8.1%. Perrigo's dividend payout ratio is -9.27%.

Hedge Funds Weigh In On Perrigo

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in Perrigo by 7.9% during the 4th quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company's stock worth $208,568,000 after purchasing an additional 1,101,154 shares in the last quarter. Bank of America Corp DE grew its stake in Perrigo by 25.5% during the first quarter. Bank of America Corp DE now owns 1,568,598 shares of the company's stock worth $16,847,000 after buying an additional 318,248 shares during the period. Thompson Siegel & Walmsley LLC increased its position in shares of Perrigo by 28.4% in the fourth quarter. Thompson Siegel & Walmsley LLC now owns 4,658,601 shares of the company's stock worth $64,848,000 after acquiring an additional 1,029,770 shares in the last quarter. Gamco Investors INC. ET AL lifted its holdings in shares of Perrigo by 29.7% during the 1st quarter. Gamco Investors INC. ET AL now owns 1,397,866 shares of the company's stock valued at $15,013,000 after acquiring an additional 320,081 shares in the last quarter. Finally, Empowered Funds LLC boosted its position in Perrigo by 41.6% during the 1st quarter. Empowered Funds LLC now owns 511,872 shares of the company's stock worth $5,498,000 after purchasing an additional 150,438 shares during the period. Institutional investors and hedge funds own 95.91% of the company's stock.

Key Perrigo News

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Zacks Research raised its FY2026 EPS forecast to $2.16 from $2.10, just below the broader consensus estimate of $2.20. It also increased its Q2 2028 estimate to $0.67 from $0.66 and lifted its Q4 2027 forecast to $0.84 from $0.72.
• Neutral Sentiment: Perrigo said Interim President and CEO Albert Manzone and CFO Eduardo Bezerra will meet with investors at the Barclays Global Consumer Conference on September 10. The event could provide updates on strategy, demand trends and the company’s outlook, but no new financial guidance was announced. Perrigo to Attend the Barclays Global Consumer Conference
• Neutral Sentiment: Zacks’ value-focused commentary comparing Perrigo with Neogen and assessing whether PRGO is attractive for value investors may support investor interest, but it does not represent a new recommendation or a material change in company fundamentals. PRGO or NEOG: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Zacks made broad downward revisions to future earnings: FY2027 EPS fell to $2.29 from $2.50, Q1 2027 declined to $0.47 from $0.60, Q2 2027 to $0.47 from $0.58, and Q3 2027 to $0.52 from $0.60. FY2028 EPS was also reduced slightly to $2.70 from $2.72.
• Negative Sentiment: Near-term estimates were cut as well, with Q3 2026 EPS lowered to $0.59 from $0.64, Q4 2026 to $0.64 from $0.72, and Q1 2028 to $0.49 from $0.70. These revisions suggest analysts see weaker or more uncertain earnings momentum ahead, likely outweighing the isolated FY2026 upgrade.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo's focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo's operations span research and development, manufacturing, quality assurance and global distribution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source